All In Biotech

Drug Trial Radar · NCT05406362

Assess Safety and Efficacy of VAD044 in HHT Patients

A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Safety and Efficacy of Two Doses of VAD044 in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

75

Actual

Start

Jul 18, 2022

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Vaderis Therapeutics AGIndustry
Sponsor type
Industry
First posted
Jun 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients. Part II: The purpose of this open-label extension following the completion of the randomised double blind treatment and follow-up period (Part I of the study) is to assess the long-term safetty, tolerability and efficacy of VAD044 in adult HHT patients.

Conditions

  • Hereditary Hemorrhagic Telangiectasia (HHT)

Interventions

  • VAD044 Part IDrug

    capsules to be taken once daily for 12 weeks

  • VAD044 Part IIDrug

    capsules to be taken once daily for 36 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I: Safety and TolerabilityTime frame: 12 weeks
  2. Part II: Safety and TolerabilityTime frame: 36 months

Locations

7 sites in 6 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Hospices Civils de Lyon

    Lyon, France

  • Ospedale Maggiore di Crema

    Crema, Italy

  • St. Antonius Hospital

    Nieuwegein, Netherlands

  • Hospital Universiati De Bellvitge

    Barcelona, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.